Cancer electrogene therapy with interleukin-12

Area of Science:

• Oncology
• Immunotherapy
• Gene Therapy

Background:

• Electrogene therapy involves delivering plasmid DNA and applying electric pulses to tissues.
• Interleukin-12 (IL-12) electrogene therapy has been extensively studied preclinically for cancer treatment.

Purpose of the Study:

• To evaluate the antitumor effectiveness of IL-12 electrogene therapy across various preclinical models.
• To understand the mechanisms underlying IL-12 electrogene therapy's efficacy.
• To assess the potential for clinical translation in oncology.

Main Methods:

• Preclinical studies involving different administration routes (intratumoral, intramuscular, peritumoral) and electric pulse protocols.
• Testing efficacy against primary tumors, distant tumors, and induced metastases.
• Investigating the induction of adaptive immunity, innate resistance, and anti-angiogenic actions.

Main Results:

• Intratumoral IL-12 electrogene therapy demonstrated high local tumor control with systemic effects.
• Intramuscular and peritumoral administration also showed significant systemic effects.
• Combination strategies with IL-12 electrogene therapy led to tumor cures in some models.

Conclusions:

• IL-12 electrogene therapy is a potent antitumor strategy with dual local and systemic effects.
• The therapy's effectiveness is mediated by immune system activation and anti-angiogenesis.
• Clinical trials in human and veterinary oncology are underway, showing encouraging results for further investigation.